Tregs, a type of CD4+ T-cell in charge of inhibiting the activation and differentiation of CD4+ helper T-cells and CD8+ cytotoxic T-cells, have been identified as a suppressor of antitumor immune responses and play a role as a primary mediator in cancer progression. This evidence concerns the gene CD4 and cancer.